Hua Yuan Zheng Quan·2026-03-16 01:12Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4][5] Core Viewpoints - The report emphasizes the importance of the PD1 plus track, highlighting numerous catalysts and opportunities within this segment. It suggests a focus on price increase expectations and the strong fundamentals of innovative drugs, indicating a favorable risk-reward ratio for certain stocks [3][5][44] - The report outlines a two-dimensional investment framework for the year, focusing on "technology innovation leadership" and "performance/valuation recovery" [6][25][44] Summary by Sections 1. Focus on Domestic Second-Generation PD1 Progress - Kangfang Biopharma's AK112 is expected to read out key clinical data for NSCLC in 2026, with global registration clinical trials accelerating [8][9] 2. Industry Viewpoints - The pharmaceutical index has shown a decline of 0.22% from March 9 to March 13, with a relative underperformance of -0.41% compared to the CSI 300 index. Notable stock performances include Yingke Medical (+35.18%) and Zhonghong Medical (+25.26%) [5][25][26] - The report identifies several companies to watch, including Heng Rui Medicine, Xin Li Tai, and Junshi Biosciences, among others, for their strong fundamentals and growth potential [5][47] 3. Investment Recommendations - The report suggests a focus on innovative drugs, AI medical technology, and surgical robots, with specific companies highlighted for their potential in these areas [44][46] - Recommendations for March include Heng Rui Medicine, Xin Li Tai, and others, while a weekly focus includes Kangfang Biopharma and Shanghai Yizhong [47]